Trial Profile
Novel autologous dendritic cell vaccine therapy targeting HTLV-1 specific antigen Combined with anti-CCR4 antibody for previously treated patients with adult T-cell leukemia. A phase Ia/Ib study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Dendritic cells (Primary) ; Mogamulizumab (Primary)
- Indications T-cell leukaemia; T-cell lymphoma
- Focus Adverse reactions
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Status changed from active, no longer recruiting to completed as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.